Cargando…
Clinical translation and implementation of optical imaging agents for precision image-guided cancer surgery
INTRODUCTION: The field of tumor-specific fluorescence-guided surgery has seen a significant increase in the development of novel tumor-targeted imaging agents. Studying patient benefit using intraoperative fluorescence-guided imaging for cancer surgery is the final step needed for implementation in...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835299/ https://www.ncbi.nlm.nih.gov/pubmed/32783112 http://dx.doi.org/10.1007/s00259-020-04970-0 |
_version_ | 1783642491040301056 |
---|---|
author | Achterberg, F. B. Deken, M. M. Meijer, R. P. J. Mieog, J. S. D. Burggraaf, J. van de Velde, C. J. H. Swijnenburg, R. J. Vahrmeijer, A. L. |
author_facet | Achterberg, F. B. Deken, M. M. Meijer, R. P. J. Mieog, J. S. D. Burggraaf, J. van de Velde, C. J. H. Swijnenburg, R. J. Vahrmeijer, A. L. |
author_sort | Achterberg, F. B. |
collection | PubMed |
description | INTRODUCTION: The field of tumor-specific fluorescence-guided surgery has seen a significant increase in the development of novel tumor-targeted imaging agents. Studying patient benefit using intraoperative fluorescence-guided imaging for cancer surgery is the final step needed for implementation in standard treatment protocols. Translation into phase III clinical trials can be challenging and time consuming. Recent studies have helped to identify certain waypoints in this transition phase between studying imaging agent efficacy (phase I–II) and proving patient benefit (phase III). TRIAL INITIATION: Performing these trials outside centers of expertise, thus involving motivated clinicians, training them, and providing feedback on data quality, increases the translatability of imaging agents and the surgical technique. Furthermore, timely formation of a trial team which oversees the translational process is vital. They are responsible for establishing an imaging framework (camera system, imaging protocol, surgical workflow) and clinical framework (disease stage, procedure type, clinical research question) in which the trial is executed. Providing participating clinicians with well-defined protocols with the aim to answer clinically relevant research questions within the context of care is the pinnacle in gathering reliable trial data. OUTLOOK: If all these aspects are taken into consideration, tumor-specific fluorescence-guided surgery is expected be of significant value when integrated into the diagnostic work-up, surgical procedure, and follow-up of cancer patients. It is only by involving and collaborating with all stakeholders involved in this process that successful clinical translation can occur. AIM: Here, we discuss the challenges faced during this important translational phase and present potential solutions to enable final clinical translation and implementation of imaging agents for image-guided cancer surgery. |
format | Online Article Text |
id | pubmed-7835299 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-78352992021-02-01 Clinical translation and implementation of optical imaging agents for precision image-guided cancer surgery Achterberg, F. B. Deken, M. M. Meijer, R. P. J. Mieog, J. S. D. Burggraaf, J. van de Velde, C. J. H. Swijnenburg, R. J. Vahrmeijer, A. L. Eur J Nucl Med Mol Imaging Original Article INTRODUCTION: The field of tumor-specific fluorescence-guided surgery has seen a significant increase in the development of novel tumor-targeted imaging agents. Studying patient benefit using intraoperative fluorescence-guided imaging for cancer surgery is the final step needed for implementation in standard treatment protocols. Translation into phase III clinical trials can be challenging and time consuming. Recent studies have helped to identify certain waypoints in this transition phase between studying imaging agent efficacy (phase I–II) and proving patient benefit (phase III). TRIAL INITIATION: Performing these trials outside centers of expertise, thus involving motivated clinicians, training them, and providing feedback on data quality, increases the translatability of imaging agents and the surgical technique. Furthermore, timely formation of a trial team which oversees the translational process is vital. They are responsible for establishing an imaging framework (camera system, imaging protocol, surgical workflow) and clinical framework (disease stage, procedure type, clinical research question) in which the trial is executed. Providing participating clinicians with well-defined protocols with the aim to answer clinically relevant research questions within the context of care is the pinnacle in gathering reliable trial data. OUTLOOK: If all these aspects are taken into consideration, tumor-specific fluorescence-guided surgery is expected be of significant value when integrated into the diagnostic work-up, surgical procedure, and follow-up of cancer patients. It is only by involving and collaborating with all stakeholders involved in this process that successful clinical translation can occur. AIM: Here, we discuss the challenges faced during this important translational phase and present potential solutions to enable final clinical translation and implementation of imaging agents for image-guided cancer surgery. Springer Berlin Heidelberg 2020-08-12 2021 /pmc/articles/PMC7835299/ /pubmed/32783112 http://dx.doi.org/10.1007/s00259-020-04970-0 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Article Achterberg, F. B. Deken, M. M. Meijer, R. P. J. Mieog, J. S. D. Burggraaf, J. van de Velde, C. J. H. Swijnenburg, R. J. Vahrmeijer, A. L. Clinical translation and implementation of optical imaging agents for precision image-guided cancer surgery |
title | Clinical translation and implementation of optical imaging agents for precision image-guided cancer surgery |
title_full | Clinical translation and implementation of optical imaging agents for precision image-guided cancer surgery |
title_fullStr | Clinical translation and implementation of optical imaging agents for precision image-guided cancer surgery |
title_full_unstemmed | Clinical translation and implementation of optical imaging agents for precision image-guided cancer surgery |
title_short | Clinical translation and implementation of optical imaging agents for precision image-guided cancer surgery |
title_sort | clinical translation and implementation of optical imaging agents for precision image-guided cancer surgery |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835299/ https://www.ncbi.nlm.nih.gov/pubmed/32783112 http://dx.doi.org/10.1007/s00259-020-04970-0 |
work_keys_str_mv | AT achterbergfb clinicaltranslationandimplementationofopticalimagingagentsforprecisionimageguidedcancersurgery AT dekenmm clinicaltranslationandimplementationofopticalimagingagentsforprecisionimageguidedcancersurgery AT meijerrpj clinicaltranslationandimplementationofopticalimagingagentsforprecisionimageguidedcancersurgery AT mieogjsd clinicaltranslationandimplementationofopticalimagingagentsforprecisionimageguidedcancersurgery AT burggraafj clinicaltranslationandimplementationofopticalimagingagentsforprecisionimageguidedcancersurgery AT vandeveldecjh clinicaltranslationandimplementationofopticalimagingagentsforprecisionimageguidedcancersurgery AT swijnenburgrj clinicaltranslationandimplementationofopticalimagingagentsforprecisionimageguidedcancersurgery AT vahrmeijeral clinicaltranslationandimplementationofopticalimagingagentsforprecisionimageguidedcancersurgery |